High-dose treatments may give faster results, while lower doses are gentler and safer for maintenance
The food noise is gone
Early data also suggest improvements in liver fat and cardiovascular markers, positioning retatrutide as a potential treatment for nonalcoholic steatohepatitis (NASH) (Zhou et al., 2023)
Lang F, Gulbins E, Lang PA, Zappulla D, Fller M
Importantly, not all variants confer increased risk: loss of function variants in HSD17B13, a lipid droplet-associated protein in hepatocytes, have been consistently associated with reduced hepatic inflammation and a lower risk of fibrosis and advanced liver disease [16]
Consequently, several studies have focused on developing benchmark resources [6, 30, 62, 68]